Systemic lupus erythematosus may present with renal manifestations that frequently are
difficult to categorize and lupus nephritis is an important predictor of poor outcome. The type …

There has long been a need for biomarkers of disease activity in lupus nephritis (LN). Such
markers ideally would be capable of detecting early sub-clinical disease and could be used …

Introduction Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease,
and kidney involvement with SLE, aka lupus nephritis (LN), is a frequent and severe …

The initial treatment of lupus nephritis is usually based on a renal biopsy. Subsequent
disease flares, however, are often treated without the benefit of kidney pathology because …

Over the past year, and for the first time ever, the US Food and Drug Administration
approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus …

Introduction Lupus nephritis (LN) affects nearly 60% of patients with systemic lupus
erythematosus and up to 30% of them will progress to end-stage renal disease (ESRD) …

Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

Objectives∼ 30% of patients with SLE develop LN. Presence and/or severity of LN are
currently assessed by renal biopsy, but biomarkers in serum or urine samples may provide …

Objective The understanding of systemic lupus erythematosus (SLE) and lupus nephritis
(LN) pathogenesis remains incomplete. This review assessed LN development in SLE …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …